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Background: Continuous flow left ventricular assist devices (CFLVADs) are now considered standard of care for end stage heart failure, 
either as bridge to transplantation or as destination therapy. Many patients with end stage heart failure also have severe, functional mitral 
regurgitation (MR). It is unclear if the mitral valve should be repaired at the time of CFLVAD implantation or if the MR will improve with left 
ventricular unloading.
methods: We retrospectively reviewed electronic medical records from a total of 131 consecutive cases of CFLVAD implantation at the 
Johns Hopkins Hospital from January 2005 to September 2012. Of the 131 patients reviewed, we identified 49 patients who survived to 
at least 1 year and had at least moderate to severe MR prior to CFLAD implantation. This study was approved by our Institution Review 
Board.
results: Of the 49 patients that had moderate to severe MR prior to CFLVAD, 40 patients improved (I) to none to mild MR, and 9 patients 
continued to have moderate to severe MR (NI) at 12 months post CFLVAD implantation. At baseline there were clinically significant 
differences in LV end diastolic dimension (7.01 + 0.09 cm (I) versus 7.46 + 0.68 cm (NI), p=0.136). At 12 months, LVEDD remained greater 
in the NI group (p=0.022). At 12 months, the NI group’s hemodynamics were also similar or superior (table). There were no differences in 
aortic insufficiency or aortic valve opening between the two groups.
conclusion:  Most patients have a reduction in mitral regurgitation after placement of a CFLVAD. Risk factors for no improvement 
include a large left ventricle at baseline and at 12 months. Despite a lack of reduction in MR in some patients, there were no differences 
in hemodynamics between the two groups. Further study should be performed to determine if repairing mitral valves at the time of LVAD 
implantation is warranted.
